Qrons (QRON) 10-Q 15 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 15, 2020
Document And Entity Information
Entity Registrant Name	Qrons Inc.
Entity Central Index Key	0001689084
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Incorporation State Country Code	WY
Entity File Number	000-55800
Is Entity's Reporting Status Current?	Yes
Is Entity Emerging Growth Company?	true
Elected Not To Use the Extended Transition Period	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Common Stock, Shares Outstanding		13,089,789
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020
Entity Shel Company	false
Entity Interactive Data Current	Yes

Balance Sheets (Unaudited)

Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 22,961	$ 67,025
Prepaid expenses	26,850	56,265
Total current assets	49,811	123,290
TOTAL ASSETS	49,811	123,290
Current liabilities
Accounts payable and accrued liabilities	153,785	140,967
Accounts payable and accrued liabilities - related party	37,488	34,907
Demand loans, related party	50,000	50,000
Advances from related party	240,000	185,000
Unsecured short-term advances	100,000	100,000
Convertible note - related party, net of debt discount	25,000	25,000
Convertible note, net of debt discount	16,646	6,171
Derivative liabilities	104,192	89,367
Total current liabilities	727,111	631,412
Total liabilities	727,111	631,412
Stockholders' equity (deficit)
Series A Preferred stock: $0.001 par value, shares authorized 10,000; 2,000 shares issued and outstanding at March 31, 2020 and December 31, 2019	2	2
Common stock, $0.0001 par value: shares authorized 100,000,000; 13,089,789 shares issued and outstanding at March 31, 2020 and December 31, 2019	1,309	1,309
Additional paid-in capital	6,632,001	6,561,047
Accumulated deficit	(7,310,612)	(7,070,480)
Total stockholder's equity (deficit)	(677,300)	(508,122)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$ 49,811	$ 123,290

Balance Sheets (Unaudited) (Par

Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Series A Preferred Shares, par value	$ 0.001	$ 0.001
Series A Preferred Shares, authorized	10,000	10,000
Series A Preferred Shares, shares issued	2,000	2,000
Series A Preferred Shares, shares outstanding	2,000	2,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	13,089,789	13,089,789
Common stock, shares outstanding	13,089,789	13,089,789

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Net sales
Operating expenses:
Research and development expenses	171,568	165,154
Professional fees	23,624	15,586
General and administrative expenses	23,746	82,774
Total operating expenses	218,938	263,514
Income (loss) from operations	(218,938)	(263,514)
Other income (expense)
Interest expense	(14,284)	(496)
Change in derivative liabilities	(6,910)	2,549
Total other income (expense)	(21,194)	2,053
Net (loss)	$ (240,132)	$ (261,461)
Net (loss) per common shares (basic and diluted)	$ (0.02)	$ (0.02)
Weighted average shares outstanding (basic and diluted)	13,089,789	12,910,865

Statement of Changes In Stockho

Statement of Changes In Stockholders Equity (Deficit) (Unaudited) - USD ($)	Series A Preferred Shares	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2018	$ 2	$ 1,287	$ 5,629,694	$ (5,523,708)	$ 107,275
Balance, shares at Dec. 31, 2018	2,000	12,872,309
Shares issued for stock awards for business advisory services		$ 3	37,497		37,500
Shares issued for stock awards for business advisory services, shares		30,000
Stock option granted to non-employees as research and development costs			45,442		45,442
Shares issued in private placement		$ 4	39,996		40,000
Shares issued in private placement, shares		40,000
Net loss for the year				(261,461)	(261,461)
Balance at Mar. 31, 2019	$ 2	$ 1,294	5,752,629	(5,785,169)	(31,244)
Balance, shares at Mar. 31, 2019	2,000	12,942,309
Balance at Dec. 31, 2019	$ 2	$ 1,309	6,561,047	(7,070,480)	(508,122)
Balance, shares at Dec. 31, 2019	2,000	13,089,789
Stock option granted to non-employees as research and development costs			67,554		67,554
Warrants granted as financing costs			3,400		3,400
Net loss for the year				(240,132)	(240,132)
Balance at Mar. 31, 2020	$ 2	$ 1,309	$ 6,632,001	$ (7,310,612)	$ (677,300)
Balance, shares at Mar. 31, 2020	2,000	13,089,789

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash Flows From Operating Activities
Net loss	$ (240,132)	$ (261,461)
Adjustments to reconcile net loss to net cash (used by) operating activities:
Stock options issued for research and development expense	67,554	45,442
Stock awards issued for advisory and consulting services		37,500
Warrants granted as financing costs	3,400
Accretion of debt discount	8,390
Change in derivative liabilities	6,910	(2,549)
Changes in operating assets and liabilities:
Prepaid expenses	29,415	30,378
Accounts payable and accrued liabilities	12,818	15,092
Accounts payable and accrued liabilities, related party	2,581	496
Net cash (used by) operating activities	(109,064)	(135,102)
Cash Flows From Investing Activities
Net cash provided from (used by) investing activities
Cash Flows From Financing Activities
Proceeds from convertible notes	10,000
Proceeds from private placement		40,000
Proceeds from related party advances	55,000
Net cash provided from financing activities	65,000	40,000
Increase (decrease) in cash and cash equivalents	(44,064)	(95,102)
Cash at beginning of year	67,025	143,862
Cash at end of year	22,961	48,760
SUPPLEMENTAL DISCLOSURES
Interest paid
Income taxes paid
SUPPLEMENTAL NON-CASH FINANCING ACTIVITIES
Derivative liability associated with debt discount	$ 7,915

Description of Business and Bas

Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	Note 1 – Description of Business and Basis of Presentation Organization and nature of business: Qrons Inc. ("Qrons" or the "Company") was incorporated under the laws of the State of Wyoming on August 22, 2016 under the name BioLabMart Inc. On July 6, 2017, the board of directors and a majority of the Company's shareholders approved an amendment to the Company's Articles of Incorporation to change the name of the Company from "BioLabMart Inc." to "Qrons Inc." On August 8, 2017, the Company filed Amended Articles of Incorporation with the State of Wyoming to effectuate such name change. The Company's common stock was approved by the Financial Industry Regulatory Authority ("FINRA") for quotation on the OTC pink sheets under the symbol "BLMB" as of July 3, 2017. FINRA announced the Company's name change to Qrons Inc. on its Daily List on August 9, 2017. The new name and symbol change to "QRON" for the OTC Market was effective August 10, 2017. The Company's common stock was upgraded from the Pink Market and commenced trading on the OTCQB Venture Market on August 12, 2019. The Company is a p reclinical stage biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions to combat neuronal injuries and focused on achieving a breakthrough in the treatment of traumatic brain injuries ("TBIs") for both concussions and penetrating injuries, an unmet medical need. The Company collaborates treatment that integrates proprietary, engineered mesenchymal stem cells (“MSCs”), synthetic hydrogels, 3D printable implant, smart materials and a novel delivery system. On March 15, 2019, the Company relocated its principal executive office from Miami, Florida to 50 Battery Place, #7T, New York, New York 10280.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Financial Statement Presentation: In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three and nine-month periods have been made. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. Use of Estimates: Cash Equivalents: Research and Development Costs: $ for the three months ended March 31, 2020 and 2019, respectively. Advertising and Marketing Costs: The Company incurred $19,500 and $48,387 in advertising and marketing costs during the three months ended March 31, 2020 and 2019, respectively. Related parties: Stock-Based Compensation and Other Share-Based Payments: Stock Plan Fair Value of Financial Instruments FASB ASC 820, Fair Value Measurements and Disclosures defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. FASB ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. FASB ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 Level 2 Level 3 If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument. The following table provides a summary of the fair value of the Company’s derivative liabilities as of March 31, 2020 and December 31, 2019: Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of March 31, 2020: Liabilities Derivative liabilities $ - $ - $ 104,192 As of December 31, 2019: Liabilities Derivative liabilities $ - $ - $ 89,367 Warrants: "Derivatives and Hedging – Contracts in Entity's Own Equity" Income taxes: Basic and Diluted Loss Per Share Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The computation of basic loss per share for the three months ended March 31, 2020 and the year ended December 31, 2019 excludes potentially dilutive securities of underlying share purchase warrants, convertible notes, stock options and preferred shares, because their inclusion would be antidilutive. As a result, the computations of net loss per share for each period presented is the same for both basic and fully diluted. The table below reflects the potentially dilutive securities at each reporting period which have been excluded from the computation of diluted net loss per share: March 31, 2020 December 31, 2019 Research Warrants at 3% of issued and outstanding shares 392,694 392,694 Convertible Notes 319,029 261,107 Series A Preferred shares 700 700 Stock options vested 2,423,335 2,331,669 Stock options not yet vested 141,665 183,331 Stock purchase warrants 80,000 70,000 Total 3,357,423 3,239,501 New Accounting Pronouncements:

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 3 – Going Concern The Company has experienced net losses to date, and it has not generated revenue from operations. While the Company raised proceeds of $65,000 during the three months ended March 31, 2020 and $470,000 during the year ended December 31, 2019, respectively, by way of private placement offerings to accredited investors, loans and advances from its officers and directors and third party short term loans, it does not believe its resources will be sufficient to meet its operating and capital needs beyond the second quarter of 2020. The Company expects it will require additional capital to fully implement the scope of its proposed business operations, which raises substantial doubt about its ability to continue as a going concern. The Company will have to continue to rely on equity and debt financing, and continued support from its officers and directors. There can be no assurance that financing, whether debt or equity, will always be available to the Company in the amount required at any particular time or for any particular period or, if available, that it can be obtained on favorable terms. In addition, if the Company is unable to obtain adequate capital due to the continued spread of COVID-19, the Company may be required to reduce the scope, delay, or eliminate some or all of its planned operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amount and classification of liabilities that might cause results from this uncertainty.

Convertible Note - Related Part

Convertible Note - Related Party and Derivative Liabilities	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Convertible Note - Related Party and Derivative Liabilities	Note 4 – Convertible Note – Related Party and Derivative Liabilities On September 1, 2016, the Company entered into a convertible debenture agreement with CubeSquare, LLC ("CubeSquare"), of which its Chief Executive Officer is the managing partner and its President is a 25% owner of CubeSquare. The Company received proceeds of $10,000 during fiscal 2016 ("Note 1"). The note bears interest at 8% per annum and was due on September 1, 2017. Interest accrues from September 1, 2016 and is payable on maturity. Interest is payable, at the lender's option, in cash or common stock. Any portion of the loan and unpaid interest is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price of the greater of (i) $0.0625 per share if the Company's shares are not trading on a public market and; (ii) in the event the Company's shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender. On September 28, 2017, the Company and CubeSquare amended Note 1 to extend the maturity date from September 1, 2017 to September 1, 2018; on September 9, 2018, the Company further amended Note 1 to extend the maturity date to September 1, 2019; and on September 1, 2019, the Company further amended Note 1 to extend the maturity date to September 1, 2020, under the same terms and conditions. On September 27, 2017, the Company entered into a second convertible debenture agreement with CubeSquare under which the Company received proceeds of $15,000 (Note 2). Note 2 bears interest at 8% per annum and was due on September 27, 2018. Interest accrues from September 27, 2017 and is payable on maturity. Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare. On September 9, 2018, Note 2 was amended to extend the maturity date until September 27, 2019. On September 27, 2019, Note 2 was amended to extend the maturity date until September 27, 2020. The Company analyzed the amendment to Note 1 and Note 2 under and concluded that these two convertible Notes We estimated the fair value of the derivative on the inception dates, and subsequently, using the Black-Scholes valuation technique, adjusted for the effect of dilution, because that technique embodies all of the assumptions (including, volatility, expected terms, and risk-free rates) that are necessary to fair value complex derivate instruments. The carrying value of these convertible notes is as follows: March 31, 2020 December 31, 2019 Face value of certain convertible notes $ 25,000 $ 25,000 Less: unamortized discount - - Carrying value $ 25,000 $ 25,000 We recorded interest expenses of $501 and $496 for the three months ended March 31, 2020 and 2019, respectively. As of March 31, 2020, and December 31, 2019, the unpaid interest balance under Accounts payable and accrued liabilities – related party was $5,933 and $5,432, respectively. As a result of the application of ASC No. 815 in the three months ended March 31, 2020, the fair value of the conversion feature is summarized as follows: Balance at December 31, 2018 $ 36,827 Change in fair value 355 Balance at December 31, 2019 37,182 Change in fair value 4,165 Balance at March 31, 2020 $ 41,347 The fair value at the commitment and re-measurement dates for the Company's derivative liabilities were based upon the following management assumptions as of March 31, 2020 and December 31, 2019 and the commitment date: Commitment Date March 31, 2020 December 31, 2019 Expected dividends 0 0 0 Expected volatility 101% ~103% 178% ~ 190% 167% ~ 180% Expected term 0.92 ~ 1 year 0.21 year 0.26 year Risk free interest rate 1.33% 0.15 1.60%

Convertible Note and Derivative

Convertible Note and Derivative Liabilities	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Convertible Note and Derivative Liabilities	Note 5 – Convertible Note and Derivative Liabilities In December 2019 we issued and sold in a private offering 8% convertible notes in the aggregate principal amount of $70,000. Such notes are due on December 31, 2021 During the three months ended March 31, 2020 we issued and sold in a private offering 8% convertible notes in the principal amount of $10,000, due on February 19, 2022 We recorded interest expenses of $1,486 for the three months ended March 31, 2020 in respect of the aforementioned notes. The convertible notes qualify for derivative accounting and bifurcation under ASC 815, “Derivatives and Hedging.” The derivative liability of the $80,000 convertible notes was calculated using the Black-Scholes pricing model to be $72,689. The carrying value of these convertible notes is as follows: March 31, 2020 December 31, 2019 Face value of certain convertible notes $ 80,000 $ 70,000 Less: unamortized discount (63,354 ) (63,829 ) Carrying value $ 16,646 $ 6,171 Amortization of the discount during the three months ended March 31, 2020 totaled $8,390 which amounts have been recorded as interest expense. As a result of the application of ASC No. 815 for the three months ended March 31, 2020 and the year ended December 31, 2019, the fair value of the conversion feature is summarized as follows: Balance at December 31, 2018 $ - Derivative addition associated with convertible notes 64,774 Change in fair value (12,589 ) Balance at December 31, 2019 52,185 Derivative addition associated with convertible notes 7,915 Change in fair value 2,745 Balance at March 31, 2020 $ 62,845 The fair value at the commitment and re-measurement dates for the Company's derivative liabilities were based upon the following management assumptions as of March 31, 2020 and December 31, 2019 and the commitment date: Commitment Date March 31, 2020 December 31, 2019 Expected dividends 0 0 0 Expected volatility 154% ~173% 177% ~ 183% 156 % Expected term 2.10 year 1.83 ~ 1.91 year 2 year Risk free interest rate 1.42 ~ 1.65% 0.23 % 1.58 %

Unsecured Short-Term Advance fr

Unsecured Short-Term Advance from Third Party	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Unsecured Short-Term Advance from Third Party	Note 6 – Unsecured Short-Term Advance from Third Party On June 20, 2019, the Company received $100,000 from a third party in the form of an unsecured, demand, non-interest bearing, short term advance to meet its operating needs. The advance remains outstanding at March 31, 2020 and December 31, 2019.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Note 7 – Related Party Transactions (1) Demand Loan from related party On May 1, 2019, the Company issued a promissory note (the "Note") to CubeSquare in the principal amount of $50,000. The Note bears interest at the rate of 8% per annum and is due and payable by the Company upon demand from CubeSquare. (2) Advances from Related Parties During the year ended December 31, 2019, the Company received $135,000 from Jonah Meer, its Chief Executive Officer, in the form of an unsecured, demand, non-interest bearing, short term advance to help meet its operating needs. During the three months ended March 31, 2020, the Company received an additional $35,000 from Jonah Meer. On August 20, 2019, the Company received $50,000 from , in the form of an unsecured, demand, non-interest bearing, short term advance to help meet its operating needs. During the three months ended March 31, 2020, the Company received an additional $10,000 from Ido Merfeld. During the three months ended March 31, 2020, the Company received $10,000 from CubeSquare, , in the form of an unsecured, demand, non-interest bearing, short term advance to help meet its operating needs. (3) Others During the year ended December 31, 2019, Jonah Meer, the Company’s Chief Executive Officer, made payments to various vendors in the accumulated amount of $25,642. Jonah Meer, the Company’s Chief Executive Officer, made payments to various vendors in the accumulated amount of $3,664, and repaid in cash of $2,092. The balance of $27,214 is reflected in accounts payable, related party. During the year ended December 31, 2019, , made payments to various vendors in the accumulated amount of $1,169. The balance of $11,169 is reflected in accounts payable, related party.

License and Research Funding Ag

License and Research Funding Agreement / Royalty Agreement	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
License and Research Funding Agreement / Royalty Agreement	Note 8 – License and Research Funding Agreement / Royalty Agreement On December 14, 2016, the Company entered into a license agreement with Ariel (the “License Agreement”) under which the Company paid Ariel $100,000 to fund research for 12 months (with an option to extend such research financing and research period). In consideration therefor, the Company received an exclusive worldwide royalty-bearing license in Ariel patents and know-how to develop and commercialize products based on or incorporating coral-based conditioned medium for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding in accordance with milestones set forth in the Agreement. In addition, upon the occurrence of an Exit Event (as defined in the License Agreement) of the Company or of any affiliate commercializing the products, the Company was obligated to issue to Ariel an immediately exercisable warrant for that number of shares equal to 4% of the issued and outstanding shares of the Company at the time of issuance. In addition to the other payments, the Company was obligated to pay Ariel upon the occurrence of the following milestone events, additional payments within 6 months of completion of the milestone: - Upon successful clinical FDA Phase II completion - $130,000; and - Upon successful clinical FDA Phase III completion - $390,000 Upon successful development and commercialization and in recognition of the rights and licenses granted to the Company pursuant to the License Agreement, the Company was subject to certain royalty payments as specified in the License Agreement. In lieu of extending the research financing and research period under the License Agreement with Ariel beyond the initial 12 months, on December 14, 2017, the Company entered into a Services Agreement (the “First Services Agreement”) pursuant to which a team at Ariel University, with Professor Danny Baranes as Principal Investigator, will conduct molecular biology research activities involving the testing of scaffold materials for the Company. As compensation for such services, the Company paid Ariel (i) $17,250 on December 19, 2017 and an additional $17,250 on April 26, 2018. On April 12, 2018, the First Services Agreement was amended (the “First Amendment”) to provide for the payment by the Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request. On March 6, 2018, the Company entered into an additional service agreement with Ariel (the “Second Services Agreement”) for the services of Professor Gadi Turgeman and his neurobiology research team in their lab pursuant to which the Company paid Ariel $20,580 on each of March 19, 2018 and August 22, 2018. On December 12, 2018, the Company further amended the First Services Agreement (the "Second Amendment") with Ariel to extend the term thereof for an additional twelve-month period until December 14, 2019. Pursuant to the Second Amendment, the Company paid Ariel $17,250 on each of December 28, 2018 and June 24, 2019. All other terms and conditions of the Services Agreement not amended remain in effect. On December 8, 2019, the Company further amended the First Services Agreement with Ariel (the "Third Amendment") to extend the term thereof for an additional twelve-month period until December 14, 2020. Pursuant to the Third Amendment, the Company paid Ariel $17,250 on January 13, 2020 and is obligated to pay Ariel an additional $17,250 by May 1, 2020 All other terms and conditions of the First Services Agreement not amended remain in effect. On July 12, 2018, the Company entered into a one-year sponsored research agreement (the “Sponsored Research Agreement”) with the Trustees of Dartmouth College (“Dartmouth”) pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the Agreement. Intellectual property invented or developed solely by a party shall be owned by such party and intellectual property jointly invented or developed shall be jointly owned. Dartmouth retains an irrevocable worldwide right to use intellectual property owned by it resulting from its research under the Agreement on a non-exclusive royalty-free basis for research and education purposes. The Agreement may be terminated earlier than one year upon written agreement of the parties, a material breach which is not cured within 30 days of notice thereof, if Professor Ke no longer conducts the research under the Agreement and a successor acceptable to both parties is not available, or in the event of an unauthorized assignment of the Company's rights and obligations under the Agreement. On November 4, 2019, the parties entered into an amendment to the Sponsored Research Agreement to extend the term of the Agreement through July 14, 2020. On November 30, 2019, the Company entered into a royalty and license fee sharing agreement (the “Royalty Agreement”) with Ariel which, among other things, supersedes and terminates the License Agreement. Certain services agreements related to laboratory access and other services are not affected by such termination. From and after the occurrence of an Exit Event, as such term is described in the Royalty Agreement, including an underwritten public offering of the Company’s shares with proceeds of at least $25 million, a consolidation, merger or reorganization of the Company, and a sale of all or substantially all of the shares and/or the assets of the Company, Ariel has the right to require the Company to issue up to 3% of the issued and outstanding shares of common stock of the Company at the time Ariel exercises such right.

Intellectual Property License A

Intellectual Property License Agreement	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intellectual Property License Agreement	Note 9 – Intellectual Property License Agreement On October 2, 2019, the Company entered into an Intellectual Property License Agreement (the “Agreement”) with the Trustees of Dartmouth College (“Dartmouth”) pursuant to which, effective September 3, 2019 (the Effective Date”), Dartmouth granted the Company an exclusive world-wide license under the patent application entitled “Mechanically Interlocked Molecules-based Materials for 3D Printing” in the field of human and animal health and certain additional patent rights to use and commercialize licensed products and services. The license grant includes the right of the Company to sublicense to third parties subject to the terms of the Agreement. Dartmouth has reserved certain rights in its intellectual property for educational and research purposes. As consideration for the license grant, the Company will pay Dartmouth: (i) a license issue fee of $25,000; (ii) an annual license maintenance fee of $25,000, commencing on the first anniversary of the Effective Date until the date of the first commercial sale of a licensed product or service; (iii) an earned royalty of 2% of net sales (as defined in the Agreement) of licensed products and services by the Company or a sublicensee; (v)15% of all consideration received by the Company under a sublicense; and (vi) beginning as of the date of the first commercial sale, an annual minimum royalty payment of $500,000 in the first calendar year after the first commercial sale, $1,000,000 in the second calendar year, and $2,000,000 in the third calendar year and each year thereafter. The Company will also reimburse Dartmouth for all patent preparation, filing, maintenance and defense costs. Under the Agreement, the Company must diligently proceed with the development, manufacture and sale of licensed products and licensed services, including funding at least $1,000,000 of research in each calendar year beginning in 2019 and ending with the first commercial sale of a licensed product; filing an IND/BLA (or equivalent) with the FDA or a comparable European regulatory agency before the four-year anniversary of the Effective Date, make the first commercial sale of a licensed product before the twelve-year anniversary of the Effective Date and achieve annual net sales of at least $50,000,000 by 2033. If the Company fails to perform any of these obligations, Dartmouth has the option to terminate the Agreement or change the exclusive license to a nonexclusive license. Failure to timely make any payment due under the Agreement will result in interest charges to the Company of the lower of 10% per year or the maximum amount of interest allowable by applicable law. The Agreement may be terminated by Dartmouth if the Company is in material breach of the Agreement which is not cured after 30 days of notice thereof or if the Company becomes insolvent. Dartmouth may terminate the Agreement if the Company challenges a Dartmouth patent or does not terminate a sublicensee that challenges a Dartmouth patent, except in response to a valid court or governmental order. The Company may terminate the Agreement at any time upon six months written notice to Dartmouth. If the Company or any sublicensee or affiliate institutes or participates in a licensed patent challenge, the then current earned royalty rate for licensed products covered by Dartmouth patents will automatically be increased to three times the then current earned royalty rate. The Agreement also includes indemnification and insurance requirements by the Company and customary confidentiality provisions. The Company recorded the $25,000 license fee under prepaid expenses, which amount shall be expensed ratably over the initial one-year term of the Agreement.

Commitments

Commitments	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments	Note 10 – Commitments (1) Service Agreement with Ariel Scientific Innovations Ltd. On December 14, 2017, the Company entered into the First Services Agreement pursuant to which a team at Ariel with Prof. Danny Baranes, as Principal Investigator, will conduct molecular biology research activities involving the testing of implant materials for the Company. As compensation for the services provided, the Company paid Ariel $17,250 on each of December 19, 2017 and April 26, 2018. On April 12, 2018, the First Services Agreement was amended to provide for the payment by the Company of an additional monthly fee, commencing March 31, 2018, of up to $2,200 (8,000 Israeli shekels) as compensation for additional costs which the Company may request. During the year ended December 31, 2018, the Company paid $16,935 for these additional costs. On December 12, 2018, the Company further amended the First Services Agreement with Ariel (the "Second Amendment") to extend the term thereof for an additional twelve-month period until December 14, 2019. Pursuant to the Second Amendment, the Company paid Ariel $17,250 on each of December 28, 2018 and June 24, 2019. All other terms and conditions of the Services Agreement not amended remain in effect. On December 8, 2019, the Company further amended the First Services Agreement with Ariel (the "Third Amendment") to extend the term thereof for an additional twelve-month period until December 14, 2020. Pursuant to the Third Amendment, the Company paid Ariel $17,250 on January 13, 2020 and is obligated to pay Ariel an additional $17,250 by May 1, 2020 All other terms and conditions of the First Services Agreement not amended remain in effect. During the three months ended March 31, 2020 and 2019, $8,625 were expensed, and the remaining $7,187 (December 31, 2019 - $15,812), which amount is reflected on the Company's balance sheets as prepaid expenses, will be expensed in a subsequent period. (2) Service Agreement with Ariel - Dr. Gadi Turgeman On March 6, 2018, the Company entered into the Second Services Agreement for the services of Professor Gadi Turgeman and his neurobiology research team in their lab. As compensation for the services provided, the Company paid Ariel $20,580 on each of March 19, 2018 and August 22, 2018. The Second Services Agreement may be terminated by the non-breaching party upon a material breach that is not cured within 30 days or by the Company upon thirty days' prior written notice to Ariel. Ariel must keep confidential information of the Company confidential for six years after the term of the Services Agreement. On April 11, 2019, the Company amended the Second Services Agreement (the "First Amendment") with Ariel which it entered into on March 6, 2018, to extend the term thereof for an additional twelve months until March 6, 2020. Pursuant to the First Amendment, the Company paid Ariel an aggregate of $41,160 in quarterly payments of $10,290 on each of April 11, 2019, June 1, 2019, September 1, 2019 and December 1, 2019 for the services of Professor Gadi Turgeman and his neurobiology research team and the use of his lab. The agreement was not renewed upon expiration. During each of the three-month periods ended March 31, 2020 and 2019, $10,290 was expensed. As part of its ongoing program of research and development, the Company has retained distinguished scientists and other qualified individuals to advise the Company with respect to its technology and business strategy and to assist it in the research, development and analysis of the Company's technology and products. In furtherance thereof, the Company has retained certain Advisors as members of its Scientific Advisory Board and Business Advisory Board as described below, and the Company and Advisors have entered into Consulting Agreements with the following terms and conditions: - Scientific Advisory Board and Consulting Services - Advisor shall provide general consulting services to Company (the "Services") as a member of its Scientific Advisory Board ("SAB"). As a member of the SAB, Advisor agrees to provide the Services as follows: (a) attending meetings of the Company's SAB; (b) performing the duties of a SAB member at such meetings, as established from time to time by the mutual agreement of the Company and the SAB members, including without limitation meeting with Company employees, consultants and other SAB members, reviewing goals of the Company and assisting in developing strategies for achieving such goals, and providing advice, support, theories, techniques and improvements in the Company's scientific research and product development activities; and (c) providing consulting services to Company at its request, including a reasonable amount of informal consultation over the telephone or otherwise as requested by Company. Advisor's consultation with Company will involve services as scientific, technical and business advisor to the Company and its management with respect to neuronal injuries and neuro degenerative diseases. - SAB Consulting Compensation - the Company shall grant to Advisor the option to purchase certain number of shares of the common stock of the Company as per the stock option award grant. The options are subject to terms and provisions of the Company's 2016 Stock Option and Stock Award Plan. (4) Business Advisory Board Agreement On January 23, 2018, the Company entered into a one-year advisory board member consulting agreement with Pavel Hilman, the controlling shareholder of Conventus Holdings SA, a BVI corporation ("Conventus"), under which Mr. Hilman will serve on the Company's Advisory Board as a business advisor. The Advisory Board Agreement will automatically renew for up to two additional one-year periods, unless earlier terminated by either party upon 30 days' prior written notice to the other party. In consideration for serving on the Advisory Board, the Company awarded 10,000 shares of its common stock to Mr. Hilman under its 2016 Stock Option and Stock Award Plan. On January 28, 2019, the Company issued 30,000 shares of common stock to Mr. Hilman for his continuing service on the Company's Advisory Board. On September 18, 2019, the Company entered into a one-year advisory board member consulting agreement with Derrick Chambers under which Mr. Chambers will serve on the Company's Advisory Board as a business advisor. The Advisory Board Agreement will automatically renew for up to two additional one-year periods, unless earlier terminated by either party upon 30 days' prior written notice to the other party. In consideration for serving on the Advisory Board, the Company awarded 25,000 shares of its common stock to Mr. Chambers under its 2016 Stock Option and Stock Award Plan, which shares were fully vested and recorded as advisory services on issuance. On February 10, 2020, the Company entered into a one-year advisory board member consulting agreement with Michael Maizel under which Mr. Maizel will serve on the Company's Advisory Board as a business advisor. The Advisory Board Agreement will automatically renew for up to two additional one-year periods, unless earlier terminated by either party upon 30 days' prior written notice to the other party. In consideration for serving on the Advisory Board, the Company granted an option to purchase 50,000 shares of common stock under the 2016 Stock Option and Award Plan subject to certain vesting terms. (5) Investor Relations Agreement On August 8, 2019, the Company entered into a six-month services agreement with PCG Advisory, Inc. ("PCG") under which agreement PCG will provide investor relations and capital market advisory services to the Company. In consideration therefor, the Company will pay PCG a monthly cash fee of $5,000 ($2,500 of which will be deferred until the Company raises at least $300,000 in a financing) and issued 50,000 shares of its common stock on August 8, 2019. After the initial six-month term, the agreement will automatically renew on a month-to-month basis unless either party notifies the other of its desire to terminate the agreement or by the Company if PCG fails to comply with securities laws, makes an untrue statement of material facts or omits to state any material fact in connection with an investment in the Company or breaches a representation, warranty or covenant in the agreement. The Company notified PCG in March 2020 that it currently was not renewing the agreement. (6) Sponsored Research Agreement On July 12, 2018, the Company entered into a one-year Sponsored Research Agreement with Dartmouth pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the Agreement. Intellectual property invented or developed solely by a party shall be owned by such party and intellectual property jointly invented or developed shall be jointly owned. Dartmouth retains an irrevocable worldwide right to use intellectual property owned by it resulting from its research under the Agreement on a non-exclusive royalty-free basis for research and education purposes. The Company funded $36,293 on August 20, 2018, $18,147 on December 17, 2018 and $18,146 on June 20, 2019. On November 4, 2019, the parties entered into an amendment to the Sponsored Research Agreement to extend the term of the Agreement through July 14, 2020. The Company funded $37,790 on November 4, 2019, $18,895 on December 1, 2019 and $18,895 on June 1, 2020. During the three months ended March 31, 2020 and 2019, $18,895 and $18,147 were expensed, respectively, and the remaining $3,150 (December 31, 2019 - $22,045), which amount is reflected on the Company's balance sheets as prepaid expenses, will be expensed in the applicable period.

Stock Plan

Stock Plan	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock Plan	Note 11 – Stock Plan 2016 Stock Option and Stock Award On December 14, 2016, the Board adopted the Company's 2016 Stock Option and Stock Award Plan (the "Plan"). The Plan provides for the award of stock options (incentive and non-qualified), stock awards and stock appreciation rights to officers, directors, employees and consultants who provide services to the Company. The terms of awards under the Plan are made by the Administrator of the Plan appointed by the Company's Board of Directors (the "Board"), or in the absence of an Administrator, by the Board. The Company has reserved 10 million shares for issuance under the Plan. Stock Awards: On January 28, 2019, the Company issued 30,000 shares to Pavel Hilman of common stock to Pavel Hilman for his continuing service on the Company's Board of Advisors. In connection with a Term Sheet, on July 1, 2019, Dr. Bonfiglio was granted (i) 50,000 shares of common stock of the Company, 37,500 of which shares vested upon issuance on July 1, 2019 and 12,500 of which shares will vest on the earlier of (i) January 1, 2020 and (ii) the date the Company raises equity capital of $500,000, provided Dr. Bonfiglio is in the employ of the Company on such date. Mr. Bonfiglio was terminated, effective November 30, 2019. All unvested stock awards were terminated on such date. On September 18, 2019, the Company awarded 25,000 shares of common stock to Derrick Chambers, a member of its advisory board, under its 2016 Stock Option and Stock Award Plan, which shares were fully vested and recorded as advisory services on issuance. March 31, March 31, 2020 2019 Number of shares vested in period - 30,000 Weighted average fair market value per share $ - $ 1.25 Stock based compensation recognized $ - $ 37,500 Stock Options: (a) Stock Options granted to Science Advisors and Business Advisors On November 15, 2017, under the 2016 Stock Option and Award Plan, the Board awarded two of its Science Advisors the following three-year stock options: (i) an immediately exercisable option to purchase 6,667 shares of common stock at an exercise price of $2.00 per share, (ii) an option to purchase 6,667 shares of common stock exercisable on November 15, 2018 at an exercise price of $2.00 per share and (iii) an option to purchase 6,666 shares of common stock exercisable on November 15, 2019 at an exercise price of $2.00 per share, provided the advisors are still providing services to the Company. On November 15, 2017, under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 15,000 shares of common stock, exercisable on November 15, 2018 at an exercise price of $0.40 per share and (ii) an option to purchase 15,000 shares of common stock exercisable on November 15, 2019 at an exercise price of $0.40 per share, provided the advisor is still providing services to the Company. On April 16, 2018, under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 10,000 shares of common stock, exercisable on April 16, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2020 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company. On August 15, 2018, under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 6,667 shares of common stock, exercisable on August 15, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 6,667 shares of common stock exercisable on August 15, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 6,666 shares of common stock exercisable on August 15, 2020 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company. On July 1, 2019, under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 33,334 shares of common stock, exercisable on July 1, 2019 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on July 1, 2020 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on July 1, 2021 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company. On February 10, 2020 the Company granted three-year options to purchase an aggregate of 50,000 shares of its common stock at an exercise price of $2.00 per share, to Michael Maizels for serving as a Business Advisor. 25,000 of such shares subject to the option were immediately exercisable and expire on February 10, 2023, and 25,000 shares vest on February 10, 2021 and expire on February 10, 2024. (b) Stock Options granted to Employees: On December 10, 2018, under the 2016 Stock Option and Award Plan, the Board awarded an employee the following three-year stock options: (i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company. On March 23, 2020, the Company accelerated the vesting provision such that options previously vesting on December 10, 2020 shall vest immediately with an expiration date of March 23, 2023. On December 10, 2019, under the 2016 Stock Option and Award Plan, the Board awarded an employee, the following three-year stock options: (i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2019 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2021 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company. On March 23, 2020, the Company accelerated the vesting provision such that options previously vesting on December 10, 2020 and December 10, 2021 shall vest immediately with an expiration date of March 23, 2023. The following table is the recognized compensation in respect of the above stock option compensation ((a) and (b)) which amount has been allocated as below: Three Months ended March 31, 2020 2019 Research and development expenses $ 67,554 $ 45,442 A s of March 31, 2020, and December 31, 2019, total unrecognized compensation remaining to be recognized in future periods totaled $63,599 and $105,683 respectively. (c) Stock Options granted to Officers: On June 25, 2019, the Company appointed John N. Bonfiglio, PhD as its chief operating officer, effective July 1, 2019. As compensation, Dr. Bonfiglio was granted a to purchase 100,000 shares of common stock at an exercise price of $2.00 per share, 50,000 of which shares vested upon grant and 25,000 shares will vest on each of July 1, 2020 and July 1, 2021, provided Dr. Bonfiglio is in the employ of the Company on such dates. If the Company raised equity capital of $1.5 million before December 31, 2019, unvested shares subject to the option will immediately vest and become exercisable, so long as Dr. Bonfiglio is in the Company's employ on such date. On December 10, 2019, the Board granted five-year options to each of its two officers . The options have an exercise price of $2.00 and are immediately exercisable. The following table is the recognized compensation in respect of the above stock option compensation, which amounts have been allocated as general and administrative expenses Three Months ended March 31, 2020 2019 General and administrative expenses $ - $ - As of March 31, 2020, and December 31, 2019, total unrecognized compensation remaining to be recognized in future periods totaled $0. The fair value of each option award referenced above is estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions at the measurement date(s): Measurement date Dividend yield 0% Expected volatility 114.69 ~ 186.80% Risk-free interest rate 1.36% ~ 2.68% Expected life (years) 3 ~ 5 Stock Price $ 0.62 ~ 2.80 Exercise Price $ 0.40 ~ 2.00 A summary of the activity for the Company's stock options at March 31, 2020 and December 31, 2019, is as follows: March 31, 2020 December 31, 2019 Weighted Average Weighted Average Shares Exercise Price Shares Exercise Price Outstanding, beginning of period 2,515,000 $ 1.97 1,615,000 $ 1.97 Granted 50,000 $ 2 950,000 $ 2 Exercised - $ - - $ - Canceled $ 2 (50,000 $ 2 Outstanding, end of period 2,565,000 $ 1.987 2,515,000 $ 1.987 Options exercisable, end of period 2,423,335 $ 1.98 2,331,669 $ 1.98 Options expected to vest, end of period 141,665 $ 1.98 183,331 $ 1.98 Weighted average fair value of options granted $ 1.60 $ 1.62

Capital Stock

Capital Stock	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Capital Stock	Note 12 – Capital Stock Authorized: The Company has authorized 100,000,000 shares of common stock, par value $0.0001, and 10,000 shares of preferred stock which is designated as Series A Preferred Stock, par value $0.001. Series A Preferred Stock: The Series A Preferred Stock is redeemable at the option of the Company at any time, in whole or in part, upon 10 trading days prior notice, at a price of $1.00 per share plus 4% per annum from the date of issuance (the "Stated Value"). The holders of the Series A Preferred Stock are entitled to a liquidation preference equal to the Stated Value, prior to the holders of other preferred stock or common stock. The holders of the Series A Preferred Stock have the right to convert such stock into common stock at a conversion rate equal to the Stated Value as of the conversion date divided by the average closing price of the common stock for the five previous trading days. The Company is required to reserve sufficient number of shares for the conversion of the Series A Preferred Stock. The holders of Class A Preferred Stock shall vote together as a single class with the holders of the Company's common stock and the holders of any other class or series of shares entitled to vote with the common stock, with the holders of Class A Preferred Stock being entitled to 66 2/3% of the total votes on There was a total of 2,000 shares of Series A Preferred Stock issued and outstanding as of March 31, 2020 and December 31, 2019. Common Stock Common stock issued during the three months ended March 31, 2020. None. Common Stock issuances during the year ended December 31, 2019 During the year ended December 31, 2019, the Company sold an aggregate of 65,000 shares of its common stock to investors and received aggregate proceeds of $65,000 pursuant to subscription agreements in private offerings. The proceeds will be used for research and general corporate purposes. On January 28, 2019, On July 1, 2019, On August 8, 2019, On September 18, 2019, During the year ended December 31, 2019, the Company shares of common stock There was a total of 13,089,789 shares of common stock issued and outstanding as of March 31, 2020 and December 31, 2019. Common Stock Purchase Warrants As of March 31, 2020 and December 31, 2019, the following common stock purchase warrants were outstanding: Warrants Weighted Average Exercise Price Outstanding – December 31, 2018 52,000 (1) $ 0.40 Granted 70,000 (3) 1.00 Forfeited/Canceled - - Exercised (52,000 ) (2) 0.40 Outstanding – December 31, 2019 70,000 1.00 Granted 10,000 (4) 1.00 Forfeited/Canceled - - Exercised - - Outstanding – March 31, 2020 80,000 $ 1.00 (1) Each two shares of common stock purchased in a private placement offering included one warrant to purchase an additional share of common stock at an exercise price of $0.40. (2) During the year ended December 31, 2019, investors exercised warrants to purchase an aggregate of 52,000 shares of common stock and received 9,980 shares for exercises on a cashless basis. (3) During the year ended December 31, 2019, the Company granted convertible notes holders accumulated 70,000 stock purchase warrants at an exercise price of $1.00. The fair value of the aforementioned warrants was $36,410 and recorded as financing cost. (4) During the three months ended March 31, 2020, the Company granted a convertible note holder 10,000 stock purchase warrants at an exercise price of $1.00. The fair value of the aforementioned warrants was $3,400 and recorded as financing cost. In accordance with authoritative accounting guidance, the fair value of the outstanding common stock purchase warrants was calculated using the Black-Scholes option-pricing model with the following assumptions at the measurement date(s): Measurement date Dividend yield 0% Expected volatility 97.90~155.19% Risk-free interest rate 0.37~1.72% Expected life (years) 2.71~5.00 Stock Price $0.25 ~ $0.65 Exercise Price $0.40 ~ $1.00

Other Events

Other Events	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Other Events	Note 13 – Other Events Due to the uncertainty caused by the current COVID-19 pandemic, on March 23, 2020, the Company gave 30 days’ notice of termination of employment to its employees. Further,

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 14 – Subsequent Events On April 21, 2020 the Company received $5,000 as a forgivable small business loan upon submission of a successful application to the Federal government as a result of the COVID 19 pandemic. The funds are intended to provide temporary economic relief to businesses that are impacted by the pandemic. The Company has evaluated events for the period from March 31, 2020 through the date of the issuance of these financial statements and determined that there are no additional events requiring disclosure.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Financial Statement Presentation	Financial Statement Presentation: In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three and nine-month periods have been made. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.
Use of Estimates	Use of Estimates:
Cash Equivalents	Cash Equivalents:
Research and Development Costs	Research and Development Costs: $ for the three months ended March 31, 2020 and 2019, respectively.
Advertising and Marketing Costs	Advertising and Marketing Costs: The Company incurred $19,500 and $48,387 in advertising and marketing costs during the three months ended March 31, 2020 and 2019, respectively.
Related parties	Related parties:
Stock-Based Compensation and Other Share-Based Payments	Stock-Based Compensation and Other Share-Based Payments: Stock Plan
Fair Value of Financial Instruments	Fair Value of Financial Instruments FASB ASC 820, Fair Value Measurements and Disclosures defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. FASB ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. FASB ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 Level 2 Level 3 If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument. The following table provides a summary of the fair value of the Company’s derivative liabilities as of March 31, 2020 and December 31, 2019: Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of March 31, 2020: Liabilities Derivative liabilities $ - $ - $ 104,192 As of December 31, 2019: Liabilities Derivative liabilities $ - $ - $ 89,367
Warrants	Warrants: "Derivatives and Hedging – Contracts in Entity's Own Equity"
Income taxes	Income taxes:
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The computation of basic loss per share for the three months ended March 31, 2020 and the year ended December 31, 2019 excludes potentially dilutive securities of underlying share purchase warrants, convertible notes, stock options and preferred shares, because their inclusion would be antidilutive. As a result, the computations of net loss per share for each period presented is the same for both basic and fully diluted. The table below reflects the potentially dilutive securities at each reporting period which have been excluded from the computation of diluted net loss per share: March 31, 2020 December 31, 2019 Research Warrants at 3% of issued and outstanding shares 392,694 392,694 Convertible Notes 319,029 261,107 Series A Preferred shares 700 700 Stock options vested 2,423,335 2,331,669 Stock options not yet vested 141,665 183,331 Stock purchase warrants 80,000 70,000 Total 3,357,423 3,239,501
New Accounting Pronouncements	New Accounting Pronouncements:

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of the fair value of derivative liabilities	Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of March 31, 2020: Liabilities Derivative liabilities $ - $ - $ 104,192 As of December 31, 2019: Liabilities Derivative liabilities $ - $ - $ 89,367
Schedule of potentially dilutive securities	March 31, 2020 December 31, 2019 Research Warrants at 3% of issued and outstanding shares 392,694 392,694 Convertible Notes 319,029 261,107 Series A Preferred shares 700 700 Stock options vested 2,423,335 2,331,669 Stock options not yet vested 141,665 183,331 Stock purchase warrants 80,000 70,000 Total 3,357,423 3,239,501

Convertible Note - Related Pa_2

Convertible Note - Related Party and Derivative Liabilities (Tables)	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Schedule of convertible notes	March 31, 2020 December 31, 2019 Face value of certain convertible notes $ 25,000 $ 25,000 Less: unamortized discount - - Carrying value $ 25,000 $ 25,000
Schedule of fair value of conversion feature	Balance at December 31, 2018 $ 36,827 Change in fair value 355 Balance at December 31, 2019 37,182 Change in fair value 4,165 Balance at March 31, 2020 $ 41,347
Schedule of fair value at commitment and re-measurement dates	Commitment Date March 31, 2020 December 31, 2019 Expected dividends 0 0 0 Expected volatility 101% ~103% 178% ~ 190% 167% ~ 180% Expected term 0.92 ~ 1 year 0.21 year 0.26 year Risk free interest rate 1.33% 0.15 1.60%

Convertible Note and Derivati_2

Convertible Note and Derivative Liabilities (Tables)	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Schedule of convertible notes derivative liabilities	March 31, 2020 December 31, 2019 Face value of certain convertible notes $ 80,000 $ 70,000 Less: unamortized discount (63,354 ) (63,829 ) Carrying value $ 16,646 $ 6,171
Schedule of fair value of conversion feature derivative liabilities	Balance at December 31, 2018 $ - Derivative addition associated with convertible notes 64,774 Change in fair value (12,589 ) Balance at December 31, 2019 52,185 Derivative addition associated with convertible notes 7,915 Change in fair value 2,745 Balance at March 31, 2020 $ 62,845
Schedule of fair value at commitment and re-measurement dates derivative liabilities	Commitment Date March 31, 2020 December 31, 2019 Expected dividends 0 0 0 Expected volatility 154% ~173% 177% ~ 183% 156 % Expected term 2.10 year 1.83 ~ 1.91 year 2 year Risk free interest rate 1.42 ~ 1.65% 0.23 % 1.58 %

Stock Plan (Tables)

Stock Plan (Tables)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of stock award	March 31, March 31, 2020 2019 Number of shares vested in period - 30,000 Weighted average fair market value per share $ - $ 1.25 Stock based compensation recognized $ - $ 37,500
Stock option compensation allocated as research and development expenses	Three Months ended March 31, 2020 2019 Research and development expenses $ 67,554 $ 45,442 Three Months ended March 31, 2020 2019 General and administrative expenses $ - $ -
Schedule of fair value options assumptions	Measurement date Dividend yield 0% Expected volatility 114.69 ~ 186.80% Risk-free interest rate 1.36% ~ 2.68% Expected life (years) 3 ~ 5 Stock Price $ 0.62 ~ 2.80 Exercise Price $ 0.40 ~ 2.00
Schedule of stock options	March 31, 2020 December 31, 2019 Weighted Average Weighted Average Shares Exercise Price Shares Exercise Price Outstanding, beginning of period 2,515,000 $ 1.97 1,615,000 $ 1.97 Granted 50,000 $ 2 950,000 $ 2 Exercised - $ - - $ - Canceled $ 2 (50,000 $ 2 Outstanding, end of period 2,565,000 $ 1.987 2,515,000 $ 1.987 Options exercisable, end of period 2,423,335 $ 1.98 2,331,669 $ 1.98 Options expected to vest, end of period 141,665 $ 1.98 183,331 $ 1.98 Weighted average fair value of options granted $ 1.60 $ 1.62

Capital Stock (Tables)

Capital Stock (Tables)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Schedule of common stock purchase warrants were outstanding	Warrants Weighted Average Exercise Price Outstanding – December 31, 2018 52,000 (1) $ 0.40 Granted 70,000 (3) 1.00 Forfeited/Canceled - - Exercised (52,000 ) (2) 0.40 Outstanding – December 31, 2019 70,000 1.00 Granted 10,000 (4) 1.00 Forfeited/Canceled - - Exercised - - Outstanding – March 31, 2020 80,000 $ 1.00
Schedule of fair value warrants assumptions	Measurement date Dividend yield 0% Expected volatility 97.90~155.19% Risk-free interest rate 0.37~1.72% Expected life (years) 2.71~5.00 Stock Price $0.25 ~ $0.65 Exercise Price $0.40 ~ $1.00

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Level 1 [Member]
Liabilities
Derivative liabilities
Level 2 [Member]
Liabilities
Derivative liabilities
Level 3 [Member]
Liabilities
Derivative liabilities	$ 104,192	$ 89,367

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Potentially dilutive securities net loss per share	3,357,423	3,239,501
Research Warrants at 3% of issued and outstanding shares [Member]
Potentially dilutive securities net loss per share	392,694	392,694
Convertible Notes [Member]
Potentially dilutive securities net loss per share	319,029	261,107
Series A Preferred shares [Member]
Potentially dilutive securities net loss per share	700	700
Stock options vested [Member]
Potentially dilutive securities net loss per share	2,423,335	2,331,669
Stock options not yet vested [Member]
Potentially dilutive securities net loss per share	141,665	183,331
Stock purchase warrants [Member]
Potentially dilutive securities net loss per share	80,000	70,000

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Accounting Policies [Abstract]
Research and development costs	$ 171,568	$ 165,154
Advertising or marketing costs	$ 19,500	$ 48,387
Research warrants issued and outstanding, percentage	3.00%

Going Concern (Details)

Going Concern (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Proceeds from loans	$ 65,000	$ 470,000

Convertible Note - Related Pa_3

Convertible Note - Related Party and Derivative Liabilities (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Carrying value	$ 25,000	$ 25,000
Related Party Debt [Member]
Face value of certain convertible notes	25,000	25,000
Less: unamortized discount
Carrying value	$ 25,000	$ 25,000

Convertible Note - Related Pa_4

Convertible Note - Related Party and Derivative Liabilities (Details 1) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Balance	$ 89,367
Balance	104,192	$ 89,367
Related Party Debt [Member]
Balance	37,182	36,827
Change in fair value	4,165	355
Balance	$ 41,347	$ 37,182

Convertible Note - Related Pa_5

Convertible Note - Related Party and Derivative Liabilities (Details 2) - Related Party Debt [Member]	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Expected dividends	0.00%	0.00%
Expected term	2 months 15 days	3 months 3 days
Risk free interest rate	0.15%	1.60%
Minimum [Member]
Expected volatility	178.00%	167.00%
Maximum [Member]
Expected volatility	190.00%	180.00%
Commitment Date [Member]
Expected dividends	0.00%
Risk free interest rate	1.33%
Commitment Date [Member] | Minimum [Member]
Expected volatility	101.00%
Expected term	11 months 1 day
Commitment Date [Member] | Maximum [Member]
Expected volatility	103.00%
Expected term	1 year

Convertible Note - Related Pa_6

Convertible Note - Related Party and Derivative Liabilities (Details Narrative) - USD ($)	Sep. 09, 2018	Sep. 28, 2017	Sep. 27, 2017	Sep. 01, 2016	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	May 01, 2020
Convertible Note - Related Party and Derivative Liabilities (Textual)
Received proceeds totaling					$ 10,000
Related Party Debt [Member]
Convertible Note - Related Party and Derivative Liabilities (Textual)
Interest expenses					501		$ 496
Accounts payable and accrued liabilities – related party					5,933		5,432
Cubesquare Llc [Member]
Convertible Note - Related Party and Derivative Liabilities (Textual)
Received proceeds totaling			$ 15,000	$ 10,000
Interest rate per annum			8.00%	8.00%				8.00%
Conversion, description			Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare.	(i) $0.0625 per share if the Company's shares are not trading on a public market and; (ii) in the event the Company's shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender.
Maturity date				Sep. 1, 2017
Maturity date, description	Note 2 was amended to extend the maturity date until September 27, 2019.	Note 1 to extend the maturity date from September 1, 2017 to September 1, 2018 and on September 9, 2018, the Company further amended Note 1 to extend the maturity date to September 1, 2019, under the same terms and conditions.
Debt instrument due date			Sep. 27, 2018
Accounts payable and accrued liabilities – related party					$ 3,671		$ 2,663
Cubesquare Llc [Member] | President [Member]
Convertible Note - Related Party and Derivative Liabilities (Textual)
Ownership percentage				25.00%

Convertible Note and Derivati_3

Convertible Note and Derivative Liabilities (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Carrying value	$ 25,000	$ 25,000
Derivative Liabilities [Member]
Face value of certain convertible notes	80,000	70,000
Less: unamortized discount	(63,354)	(63,829)
Carrying value	$ 16,646	$ 6,171

Convertible Note and Derivati_4

Convertible Note and Derivative Liabilities (Details 1) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Balance	$ 89,367
Balance	104,192	$ 89,367
Derivative Liabilities [Member]
Balance	52,185
Derivative addition associated with convertible notes	7,915	64,774
Change in fair value	(2,745)	(12,589)
Balance	$ 62,845	$ 52,185

Convertible Note and Derivati_5

Convertible Note and Derivative Liabilities (Details 2) - Derivative Liabilities [Member]	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Expected dividends	0.00%		0.00%
Expected volatility			156.00%
Expected term			2 years
Risk free interest rate	0.23%		1.58%
Commitment Date [Member]
Expected dividends	0.00%
Expected term	2 years 1 month 7 days
Risk free interest rate	1.58%
Minimum [Member]
Expected volatility		177.00%
Expected term		1 year 9 months 28 days
Minimum [Member] | Commitment Date [Member]
Expected volatility	154.00%
Risk free interest rate	1.42%
Maximum [Member]
Expected volatility		183.00%
Expected term		1 year 11 months 4 days
Maximum [Member] | Commitment Date [Member]
Expected volatility	173.00%
Risk free interest rate	1.65%

Convertible Note and Derivati_6

Convertible Note and Derivative Liabilities (Details Narrative) - Derivative Liabilities [Member]	3 Months Ended
	Mar. 31, 2020USD ($)
Derivative liability convertible notes	$ 80,000
Interest rate per annum	8.00%
Derivative liability	$ 72,689
Interest expenses	1,486
Amortization	$ 8,390

Unsecured Short-Term Advance _2

Unsecured Short-Term Advance from Third Party (Details Narrative) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
Unsecured short-term advances	$ 100,000	$ 100,000

Related Party Transaction (Deta

Related Party Transaction (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2020	May 01, 2020	Dec. 31, 2019	Aug. 20, 2019	Sep. 27, 2017	Sep. 01, 2016
Due to related party	$ 50,000		$ 50,000
Due to related party vendor payment	27,214
General and administrative expenses	93,300
Stock option - 50,000 vested shares [Member]
General and administrative expenses	44,175
Stock award - 37,500 vested shares [Member]
General and administrative expenses	49,125
Cubesquare Llc [Member]
Due to related party	10,000	$ 50,000
Interest percentage		8.00%			8.00%	8.00%
Interest expenses	1,008
Accounts payable and accrued liabilities	3,671		2,663
Jonah Meer [Member]
Due to related party	35,000		$ 135,000
Due to related party vendor payment	25,642
Merfeld [Member]
Due to related party	10,000			$ 50,000
Due to related party vendor payment	$ 11,169			$ 2,092

License and Research Funding _2

License and Research Funding Agreements (Details Narrative) - USD ($)	Aug. 08, 2019	Jul. 10, 2019	Mar. 06, 2018	Dec. 13, 2017	Dec. 14, 2016	Sep. 18, 2019	Apr. 23, 2018	Jan. 23, 2018	Mar. 31, 2020	Mar. 31, 2019
License and Research Funding Agreements (Textual)
Research and development costs									$ 171,568	$ 165,154
Shares issued for advisory services, value	50,000	37,500				25,000	75,000	10,000
Shares issued, value	$ 74,500	$ 49,125				$ 40,250		$ 28,000		$ 40,000
License and research funding agreement compensation paid, description			the Company entered into an additional service agreement with Ariel for the services of Professor Gadi Turgeman and his neurobiology research team in their lab pursuant to which the Company paid Ariel $20,580 on each of March 19, 2018 and August 22, 2018.						The Company paid Ariel (i) $17,250 on December 19, 2017 and an additional $17,250 on April 26, 2018. On April 12, 2018, the Services Agreement was amended to provide for the payment by the Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request.
Licensing Agreements [Member]
License and Research Funding Agreements (Textual)
Total amount of fund for research during research period					$ 100,000
Warrant exercisable percentage					4.00%
Payments of completion of milestone events, description					Upon successful clinical FDA Phase II completion - $130,000; and Upon successful clinical FDA Phase III completion - $390,000
Payments of completion of milestone events due					6 months
Ariel University [Member]
License and Research Funding Agreements (Textual)
Shares issued for advisory services, value				119,950
Shares issued, value				$ 335,860
Shares issued, percentage				1.00%

Intellectual Property License_2

Intellectual Property License Agreement (Details Narrative)	3 Months Ended
	Mar. 31, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Licence fee	$ 25,000
Royalty expense	50,000
Prepaid expense	$ 25,000

Commitments (Details Narrative)

Commitments (Details Narrative) - USD ($)

Aug. 08, 2019

Jul. 10, 2019

Jul. 12, 2018

Jun. 23, 2018

Apr. 12, 2018

Sep. 18, 2019

Jan. 28, 2019

Apr. 23, 2018

Jan. 23, 2018

Jan. 23, 2018

Nov. 15, 2017

Mar. 31, 2020

Mar. 31, 2019

Dec. 31, 2019

Aug. 22, 2018

Jun. 30, 2018

May 01, 2018

Apr. 26, 2018

Mar. 19, 2018

Dec. 14, 2017

Commitments (Textual)

Compensation for the services provided

$ 17,250

$ 17,250

$ 17,250

Compensation cost

$ 8,625

$ 8,625

Advisors are granted the option

10,000

[1]

70,000

[2]

Service agreement payment, description

the Company of an additional monthly fee, commencing March 2018, of up to $2,200 (8,000 Israeli shekels) as compensation for additional costs which the Company may request.quest.

Prepaid expenses

$ 7,187

15,812

Prepaid expensed during period

25,000

Investor relations agreement, description

The Company gave notice of rescission of the agreement to such firm and requested the return of the consulting fee paid and the 75,000 shares of common stock. As a result, the Company has not recorded any fees for services rendered past June 23, 2018. A total of $10,000 representing April 2018 and May 2018 monthly consulting fees is reflected in the statement of operations and a total of $150,000, the fair market value of the issued shares, was expensed on issue.

The Company issued 75,000 shares of its common stock in respect of an investor relations services agreement which was rescinded on June 23, 2018 (Note 6(5)). The shares were valued at the fair market value on the date of issuance for a total of $150,000, or $2.00 per share.

Paid for additional fees

16,935

Issuance of common stock payable

50,000

37,500

25,000

75,000

10,000

Sponsored Research Agreement [Member]

Commitments (Textual)

Prepaid expenses

18,895

$ 18,147

0

Prepaid expensed during period

3,150

$ 22,045

Sponsored research agreement, description

The Company entered into a one-year sponsored research agreement (the "Sponsored Research Agreement"), with the Trustees of Dartmouth College ("Dartmouth") pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the Agreement. Intellectual property invented or developed solely by a party shall be owned by such party and intellectual property jointly invented or developed shall be jointly owned. Dartmouth shall retain an irrevocable worldwide right to use intellectual property owned by it resulting from its research under the Agreement on a non-exclusive royalty-free basis for research and education purposes. The Company funded $36,293 on August 20, 2018 and will fund additional $18,147 by December 1, 2018 and $18,146 by June 1, 2019, respectively.

Service Agreement With Ariel [Member]

Commitments (Textual)

Compensation for the services provided

41,160

$ 20,580

$ 20,580

$ 17,250

Compensation cost

10,290

Prepaid expenses

10,290

$ 10,290

$ 0

Prepaid expensed during period

$ 0

Equity Option [Member]

Commitments (Textual)

Advisors are granted the option

10,000

20,000

Issuance of common stock payable

30,000

[1]

During the three months ended March 31, 2020, the Company granted a convertible note holder 10,000 stock purchase warrants at an exercise price of $1.00. The fair value of the aforementioned warrants was $3,400 and recorded as financing cost.

[2]

During the year ended December 31, 2019, the Company granted convertible notes holders accumulated 70,000 stock purchase warrants at an exercise price of $1.00. The fair value of the aforementioned warrants was $36,410 and recorded as financing cost.

Stock Plan (Details)

Stock Plan (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement [Abstract]
Number of shares vested in period		30,000
Weighted average fair market value per share		$ 1.25
Stock based compensation recognized		$ 37,500

Stock Plan (Details 1)

Stock Plan (Details 1) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Research and Development Expense [Member]
Stock option compensation allocated expenses	$ 67,554	$ 45,442
General and Administrative Expense [Member]
Stock option compensation allocated expenses

Stock Plan (Details 2)

Stock Plan (Details 2) - Measurement Date [Member] - Equity Option [Member]	3 Months Ended
	Mar. 31, 2020$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Exercise Price, Minimum	$ 0.40
Exercise Price, Maximum	$ 2
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	114.69%
Risk-free interest rate	1.36%
Expected life (years)	3 years
Stock Price	$ 0.62
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	186.80%
Risk-free interest rate	2.68%
Expected life (years)	5 years
Stock Price	$ 2.80

Stock Plan (Details 3)

Stock Plan (Details 3) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Shares Outstanding, beginning of period	2,515,000	1,615,000
Shares, Granted	50,000	950,000
Shares, Exercised
Shares, Canceled		(50,000)
Shares Outstanding, end of period	2,565,000	2,515,000
Shares Options exercisable, end of period	2,423,335	2,331,669
Shares, Options expected to vest, end of period	141,665	183,331
Weighted Average Shares Exercise Price, Outstanding, beginning of period	$ 1.987	$ 1.97
Weighted Average Shares Exercise Price, Granted	2	2
Weighted Average Shares Exercise Price, Exercised
Weighted Average Exercise Price, Canceled	2	2
Weighted Average Shares Exercise Price, Outstanding, end of period	1.987	1.987
Weighted Average Exercise Price, Options exercisable, end of period	1.98	1.98
Weighted Average Exercise Price, Options expected to vest, end of period	1.98	1.98
Weighted Average Exercise Price, Weighted average fair value of options granted	$ 1.60	$ 1.62

Stock Plan (Details Narrative)

Stock Plan (Details Narrative) - USD ($)	Feb. 10, 2020	Dec. 10, 2019	Dec. 10, 2018	Aug. 15, 2018	Jul. 31, 2019	Apr. 16, 2018	Nov. 15, 2017	Mar. 31, 2020	Dec. 04, 2017	Dec. 14, 2016
Stock Plan (Textual)
Total unrecognized compensation remaining to be recognized in future periods								$ 110,156
Board of Directors Chairman [Member]
Stock Plan (Textual)
Stock award										440,000
Stock Option One [Member]
Stock Plan (Textual)
Description of services agreement	Company granted three-year options to purchase an aggregate of 50,000 shares of its common stock at an exercise price of $2.00 per share, to Michael Maizels for serving as a Business Advisor. 25,000 of such shares subject to the option were immediately exercisable and expire on February 10, 2023, and 25,000 shares vest on February 10, 2021 and expire on February 10, 2024.	Under the 2016 Stock Option and Award Plan, the Board awarded an employee, the following three-year stock options: (i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2019 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2021 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company			Under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 33,334 shares of common stock, exercisable on July 1, 2019 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on July 1, 2020 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on July 1, 2021 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company.		Under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 15,000 shares of common stock, exercisable on November 15, 2018 at an exercise price of $0.40 per share and (ii) an option to purchase 15,000 shares of common stock exercisable on November 15, 2019 at an exercise price of $0.40 per share, provided the advisor is still providing services to the Company.
Equity Option [Member]
Stock Plan (Textual)
Reserved shares for issuance										10
Description of services agreement				Under the 2016 Stock Option and Award Plan, the Board granted a Science Advisor an option to purchase an aggregate of 20,000 shares of common stock at an exercise price of $2.00 per share. The option vests as to 6,667 shares on each of August 15, 2018 and August 15, 2019 and as to 6,666 shares on August 15, 2020 and remains exercisable as to each such installment for three years from the date of vesting.		Under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 10,000 shares of common stock, exercisable on April 16, 2018 at an exercise price of $2.00 per share and (ii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2020 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company. provided the advisor is still providing services to the Company.	Under the 2016 Stock Option and Award Plan, the Board awarded two of its Science Advisors the following three-year stock options: (i) an immediately exercisable option to purchase 6,667 shares of common stock at an exercise price of $2.00 per share, (ii) an option to purchase 6,667 shares of common stock exercisable on November 15, 2018 at an exercise price of $2.00 per share and (iii) an option to purchase 6,666 shares of common stock exercisable on November 15, 2019 at an exercise price of $2.00 per share, provided the advisors are still providing services to the Company.
Stock Options Granted To Officers [Member]
Stock Plan (Textual)
Total unrecognized compensation remaining to be recognized in future periods								$ 0
Weighted average exercise price		$ 2	$ 2						$ 2
Granted an option to purchase shares of common stock		325,000
Stock Options Granted Employees [Member]
Stock Plan (Textual)
Description of services agreement			(i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share
Weighted average exercise price			$ 2
Fourth Quarter [Member] | Stock Awards Not Yet Vested [Member]
Stock Plan (Textual)
Vested shares								290,000
December Fourteen Two Zero One Eight [Member] | Board of Directors Chairman [Member]
Stock Plan (Textual)
Vested shares								145,000

Capital Stock (Details)

Capital Stock (Details) - $ / shares	3 Months Ended		12 Months Ended
	Mar. 31, 2020		Dec. 31, 2019
Equity [Abstract]
Warrants Outstanding Beginning	70,000		52,000	[1]
Warrants Granted	10,000	[2]	70,000	[3]
Warrants Forfeited/Canceled
Warrants Exercised			(52,000)	[4]
Warrants Outstanding Ending	80,000		70,000
Weighted Average Exercise Price Outstanding Beginning	$ 1		$ 0.40
Weighted Average Exercise Price Granted	1		1
Weighted Average Exercise Price Forfeited/Canceled
Weighted Average Exercise Price Exercised			0.40
Weighted Average Exercise Price Outstanding Ending	$ 1		$ 1
[1]	Each two shares of common stock purchased in a private placement offering included one warrant to purchase an additional share of common stock at an exercise price of $0.40.
[2]	During the three months ended March 31, 2020, the Company granted a convertible note holder 10,000 stock purchase warrants at an exercise price of $1.00. The fair value of the aforementioned warrants was $3,400 and recorded as financing cost.
[3]	During the year ended December 31, 2019, the Company granted convertible notes holders accumulated 70,000 stock purchase warrants at an exercise price of $1.00. The fair value of the aforementioned warrants was $36,410 and recorded as financing cost.
[4]	During the year ended December 31, 2019, investors exercised warrants to purchase an aggregate of 52,000 shares of common stock and received 9,980 shares for exercises on a cashless basis.

Capital Stock (Details 1)

Capital Stock (Details 1) - Measurement Date [Member] - Warrant [Member]	3 Months Ended
	Mar. 31, 2020$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	97.90%
Risk-free interest rate	0.37%
Expected life (years)	2 years 8 months 16 days
Stock Price	$ 0.25
Exercise Price	$ 0.40
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	155.19%
Risk-free interest rate	1.72%
Expected life (years)	5 years
Stock Price	$ 0.65
Exercise Price	$ 1

Capital Stock (Details Narrativ

Capital Stock (Details Narrative) - USD ($)	Aug. 08, 2019	Jul. 10, 2019	Sep. 18, 2019	Apr. 23, 2018	Jan. 23, 2018	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Series A Preferred Shares, par value						$ 0.001		$ 0.001
Series A Preferred Shares, authorized						10,000		10,000
Series A Preferred Shares, shares issued						2,000		2,000
Series A Preferred Shares, shares outstanding						2,000		2,000
Common stock, par value						$ 0.0001		$ 0.0001
Common stock, shares authorized						100,000,000		100,000,000
Common stock, shares issued						13,089,789		13,089,789
Common stock, shares outstanding						13,089,789		13,089,789
Shares issued in private placement, shares	50,000	37,500	25,000	75,000	10,000
Issuance of common stock for private placement	$ 74,500	$ 49,125	$ 40,250		$ 28,000		$ 40,000
Share price per share	$ 1.49	$ 1.31	$ 1.61		$ 2.80
Warrants exercised								52,000	[1]
Investor
Shares issued in private placement, shares							75,000
Issuance of common stock for private placement							$ 150,000
Share price per share							$ 2
Common Stock
Shares issued in private placement, shares							40,000
Issuance of common stock for private placement							$ 4
Share price per share						$ 2.80
Common Stock | Advisory Services
Shares issued for stock awards for business advisory services, shares						30,000
Shares issued for stock awards for business advisory services						$ 37,500
Additional Paid-In Capital
Issuance of common stock for private placement							$ 39,996
[1]	During the year ended December 31, 2019, investors exercised warrants to purchase an aggregate of 52,000 shares of common stock and received 9,980 shares for exercises on a cashless basis.

Subsequent Events (Details)

Subsequent Events (Details)	1 Months Ended
	Apr. 21, 2020USD ($)
Subsequent Event [Member]
Debt forgiveness amount	$ 5,000